Kidney Cancer: Now Available in a New Flavor

Slides:

Advertisements

Similar presentations

Individualized Medicine from Prewomb to Tomb Eric J. Topol Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell Copyright.

Advertisements

What We Talk About When We Talk About Fat Evan D. Rosen, Bruce M. Spiegelman Cell Volume 156, Issue 1, Pages (January 2014) DOI: /j.cell

Latent Bone Metastasis in Breast Cancer Tied to Src-Dependent Survival Signals Xiang H.-F. Zhang, Qiongqing Wang, William Gerald, Clifford A. Hudis, Larry.

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

Maintaining Cell Identity through Global Control of Genomic Organization Gioacchino Natoli Immunity Volume 33, Issue 1, Pages (July 2010) DOI: /j.immuni

UvrD Helicase Unwinds DNA One Base Pair at a Time by a Two-Part Power Stroke Jae Young Lee, Wei Yang Cell Volume 127, Issue 7, Pages (December.

Tumor-Derived Jagged1 Promotes Osteolytic Bone Metastasis of Breast Cancer by Engaging Notch Signaling in Bone Cells Nilay Sethi, Xudong Dai, Christopher.

Eph-Ephrin Bidirectional Signaling in Physiology and Disease Elena B. Pasquale Cell Volume 133, Issue 1, Pages (April 2008) DOI: /j.cell

Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer Min Ni, Yiwen Chen, Elgene Lim, Hallie Wimberly, Shannon T. Bailey, Yuuki Imai,

C/EBPβ at the core of the TGFβ cytostatic response and its evasion in metastatic breast cancer cells Roger R. Gomis, Claudio Alarcón, Cristina Nadal, Catherine.

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.

The Landscape of Microsatellite Instability in Colorectal and Endometrial Cancer Genomes Tae-Min Kim, Peter W. Laird, Peter J. Park Cell Volume 155, Issue.

Human Brown Adipose Tissue Sven Enerbäck Cell Metabolism Volume 11, Issue 4, Pages (April 2010) DOI: /j.cmet Copyright © 2010.

Fate Restriction and Multipotency in Retinal Stem Cells Lázaro Centanin, Burkhard Hoeckendorf, Joachim Wittbrodt Cell Stem Cell Volume 9, Issue 6, Pages.

Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung Zvi Granot, Erik Henke, Elizabeth A. Comen, Tari A. King, Larry Norton, Robert Benezra.

Myc Represses Primitive Endoderm Differentiation in Pluripotent Stem Cells Keriayn N. Smith, Amar M. Singh, Stephen Dalton Cell Stem Cell Volume 7, Issue.

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.

A Conditional Mouse Model of Synovial Sarcoma: Insights into a Myogenic Origin Malay Haldar, Jeffrey D. Hancock, Cheryl M. Coffin, Stephen L. Lessnick,

Gastrulation Movements: the Logic and the Nuts and Bolts Maria Leptin Developmental Cell Volume 8, Issue 3, Pages (March 2005) DOI: /j.devcel

The Kinase-Independent, Second Life of CDK6 in Transcription

Cancer: Inappropriate Expression of Stem Cell Programs?

Building better therapy for children with acute lymphoblastic leukemia

We Contain Multitudes: The Protean Face of Retinoblastoma

“Atypical” Regulation of Hedgehog-Dependent Cancers

Volume 25, Issue 4, Pages (April 2014)

Linking miRNA Regulation to BCR-ABL Expression: The Next Dimension

Warren S. Pear, M. Celeste Simon Cancer Cell

VHL Inactivation: A New Road to Senescence

Wild-Type RAS: Keeping Mutant RAS in CHK

Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer

Volume 11, Issue 4, Pages (April 2007)

Three Down and One To Go: Modeling Medulloblastoma Subgroups

Tailor-Made Renal Cell Carcinoma Vaccines

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

MDS Is a Stem Cell Disorder After All

DAISY: Picking Synthetic Lethals from Cancer Genomes

Volume 26, Issue 1, Pages 1-2 (July 2014)

T.S. Karin Eisinger-Mathason, M. Celeste Simon Cancer Cell

Kidney Cancer: Now Available in a New Flavor

ABT-199: Taking Dead Aim at BCL-2

Pancreatic Cancer—Could It Be that Simple

A Radical Role for p38 MAPK in Tumor Initiation

Raf-1 and Squamous Cell Carcinoma: Rok-ing the Boat

Sumoylation Stabilizes Smoothened to Promote Hedgehog Signaling

William G. Kaelin, Peter J. Ratcliffe Molecular Cell

The great MYC escape in tumorigenesis

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

FAL1ing inside an Amplicon

Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy Laurence Blavier, Yves A. DeClerck

An Integrin-Linked Machinery of Cytoskeletal Regulation that Enables Experimental Tumor Initiation and Metastatic Colonization Tsukasa Shibue, Mary W.

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Volume 143, Issue 6, (December 2010)

Volume 14, Issue 4, Pages (October 2008)

Volume 16, Issue 3, Pages (September 2009)

A common pathway for genetic events leading to pheochromocytoma

To Infinium, and Beyond! Cancer Cell

FAL1ing inside an Amplicon

Volume 10, Issue 3, Pages (September 2006)

Chapter 29 - Stem Cells and Generation of New Cells in the

ROS: Really involved in Oxygen Sensing

Macrophage Metabolism Shapes Angiogenesis in Tumors

There's a Time and a Place for MYCN

Volume 17, Issue 2, Pages (February 2010)

Gankyrin: An intriguing name for a novel regulator of p53 and RB

Ibrutinib Treatment of CLL: The Cancer Fights Back

Volume 12, Issue 6, Pages (December 2007)

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Presentation transcript:

Kidney Cancer: Now Available in a New Flavor William G. Kaelin Cancer Cell Volume 14, Issue 6, Pages 423-424 (December 2008) DOI: 10.1016/j.ccr.2008.11.005 Copyright © 2008 Elsevier Inc. Terms and Conditions

Figure 1 Clear Cell Renal Carcinoma Subtypes pVHL targets HIFα for proteasomal degradation. Accordingly, tumors with wild-type pVHL have low levels of HIFα. pVHL-defective tumors can be subdivided based on whether they accumulate both HIF1α and HIF2α (H1H2) or HIF2α alone (H2). In the former, HIF1α antagonizes c-Myc. In the latter, this antagonism is lost and c-Myc activity is therefore increased. Cancer Cell 2008 14, 423-424DOI: (10.1016/j.ccr.2008.11.005) Copyright © 2008 Elsevier Inc. Terms and Conditions